{"id":"NCT03950674","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study","officialTitle":"A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02-22","primaryCompletion":"2019-05-20","completion":"2023-06-22","firstPosted":"2019-05-15","resultsPosted":"2020-06-11","lastUpdate":"2024-06-10"},"enrollment":40,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small-Cell Lung Carcinoma"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab 200 mg","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Pemetrexed","otherNames":[]},{"type":"DIETARY_SUPPLEMENT","name":"Folic acid 350-1000 μg","otherNames":[]},{"type":"DIETARY_SUPPLEMENT","name":"Vitamin B12 1000 μg","otherNames":[]},{"type":"DRUG","name":"Dexamethasone 4 mg","otherNames":[]},{"type":"DRUG","name":"Saline solution","otherNames":[]}],"arms":[{"label":"Pembrolizumab with Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and Pemetrexed","type":"EXPERIMENTAL"},{"label":"Placebo with Pemetrexed and Platinum Chemotherapy Followed by Placebo and Pemetrexed","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Japan Extension Study of Global Study MK-3475-189 (NCT02578680). This is an efficacy and safety study of pembrolizumab (MK-3475) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy alone in adult Japanese participants with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for advanced disease. Participants will be randomly assigned to receive pembrolizumab combined with pemetrexed/platinum (Investigators choice of cisplatin or carboplatin), OR pemetrexed/platinum (Investigators choice of cisplatin or carboplatin).\n\nWith Amendment 11 (effective date 31-Jan-2022), once the study objectives have been met or the study has ended, participants will be discontinued from this study and will be enrolled in an extension study to continue protocol-defined assessments and treatment.\n\nThe primary hypothesis is that pembrolizumab in combination with pemetrexed/platinum chemotherapy prolongs Progression-Free Survival (PFS) and Overall Survival (OS) compared to pemetrexed/platinum chemotherapy alone.","primaryOutcome":{"measure":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging","timeFrame":"Up to approximately 31 months","effectByArm":[{"arm":"Pembrolizumab With Pemetrexed and Platinum Chemotherapy Followed by Pembrolizumab and Pemetrexed","deltaMin":16.5,"sd":null},{"arm":"Placebo With Pemetrexed and Platinum Chemotherapy Followed by Placebo and Pemetrexed","deltaMin":7.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.12511"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":25},"locations":{"siteCount":10,"countries":["Japan"]},"refs":{"pmids":["34036692","37465924","35930972"],"seeAlso":["https://www.merckclinicaltrials.com/"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":25},"commonTop":["Constipation","Nausea","Decreased appetite","Anaemia","Alanine aminotransferase increased"]}}